SBA
ALXN

Seven Bridges Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Seven Bridges Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,899
Closed -$347K – 109
2017
Q4 		$347K Hold
2,899
– – 0.28% 79
2017
Q3 		$407K Buy
2,899
+261
+10% +$35.5K 0.34% 77
2017
Q2 		$321K Buy
2,638
+53
+2% +$6.17K 0.29% 78
2017
Q1 		$313K Buy
2,585
+578
+29% +$74.5K 0.3% 87
2016
Q4 		$246K Buy
2,007
+246
+14% +$30.1K 0.25% 93
2016
Q3 		$216K Sell
1,761
-276
-14% -$35.5K 0.19% 96
2016
Q2 		$238K Sell
2,037
-770
-27% -$109K 0.2% 93
2016
Q1 		$391K Buy
2,807
+365
+15% +$53.6K 0.31% 80
2015
Q4 		$466K Buy
+2,442
New +$427K 0.47% 66

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Seven Bridges Advisors's ALXN Position: Q1 2018 in Review

Seven Bridges Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 2,899 shares — an estimated $347K sold.

Seven Bridges Advisors first reported a position in ALXN in Q4 2015 and held it in 9 quarters. The position peaked at $466K in Q4 2015. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Seven Bridges Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Seven Bridges Advisors sold 2,899 Alexion Pharmaceuticals shares in Q1 2018, an estimated $347K.
  • Seven Bridges Advisors first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Seven Bridges Advisors's Alexion Pharmaceuticals position peaked at $466K in Q4 2015.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Seven Bridges Advisors's 13F filing for Q1 2018, filed 9 May 2018.